Alopecia areata (AA) is a chronic and highly unpredictable autoimmune disorder affecting growing hair follicles in susceptible individuals, which results in non-scarring hair loss and negatively impacts quality of life. Current treatment options include topical and systemic steroids, steroid injections, minoxidil, and topical sensitizers. Emerging research on AA immunopathogenesis shows that local inflammation in AA is largely mediated by the Janus kinase(JAK)/signal transducer and activator of transcription (STAT) pathway; this has led to the rapid development of JAK inhibitors as a breakthrough therapeutic option for AA.
This program has received financial support from Pfizer and ICE-BM in the form of an unrestricted educational grant.